UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29

Benzinga · 2d ago
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.